Recursion Pharmaceuticals
Chris completed his Ph.D. in bioengineering at the University of Utah in the Fall of 2013 before taking a leave of absence from medical school to found and grow Recursion. He developed the core technology underlying this venture while in the lab of Dr. Dean Li. Chris comes from a family of entrepreneurs, is a graduate of Rice University with degrees in bioengineering and managerial studies and has completed an intense course in entrepreneurship at Stanford GSB.
Chris is also a Board Member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia, and Recursion's first spin-co, CereXis, Inc. Chris enjoys cycling on both the road and the trails that cut through Utah's great wilderness, as well as spending precious time with his family. To read more about Chris’s inspiration for co-founding Recursion, go here.
Recursion Pharmaceuticals
13 followers
Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease.